

### **Screening: PSA test is not the answer**

Mark R. Haythorn and Richard J. Ablin, pp.16-17

#### References:

1. Ablin, R.J., Soanes, W.A., Bronson, P., and Witebsky, E., *Precipitating antigens of the normal human prostate*. J Reprod Fert, 1970a. **22**:573-4.
2. Ablin, R.J., Bronson, P., Soanes, W.A., and Witebsky, E., *Tissue- and species-specific antigens of normal human prostatic tissue*. J Immunol, 1970b. **104**:1329-39.
3. Ablin, R.J., *Immunologic studies of normal, benign and malignant human prostatic tissue*. Cancer, 1972. **29**:1570-4.
4. Andriole, G.L., Grubb, R.L. III, Buys, S.S., et al., *Mortality results from a randomized prostate-cancer screening trial*. N Eng J Med, 2009. **360**:1310-9.
5. Schröder, F.H., Hugosson, J., Roobol M.J., et al., *Screening and prostate-cancer mortality in a randomized European study*. N Eng J Med, 2009. **360**:1320-8
6. De Koning, H.J., Blom, J., Merkelbach, J.W., et al., *Determining the cause of death in randomized screening trial(s) for prostate cancer*. BJU Intl, 2003. **92**:71-8.
7. Sakr, W.A., Grigon, D.J., Haas, G.P., et al., *Age and racial distribution of prostatic intraepithelial neoplasia*. Eur Urol, 1996. **30**:138-44.
8. Welch, H.G., and Albertsen, P.C., *Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005*. J Natl Cancer Inst, 2005.**101** [Aug. 31, Epub ahead of print.]

## **Surviving cancer, living life: a nurse-led telephone service**

Jan Hanson and Jannike Nordlund, pp. 18-19

### References:

1. Macmillan Cancer Support booklet, *Two Million Reasons*, Sept 2008.
2. Department of Health, *Cancer Reform Strategy*, 2007.
3. Ream, Richardson, et al., *Supportive care needs of men living with prostate cancer in England*. Br J Cancer Res, 2008.
4. Richardson, John, et al, *Surviving Cancer Living Life Support Service: An Evaluation*, July 2009

## Promoting bone health in men with prostate cancer

Kay Leonard, pp.20-23

### References

1. Michaud, L.B., and Goodin, S., Cancer-treatment-induced bone loss, part 1. *Am J Health-Syst Pharm*, 2006. **63**: 419-30.
2. Spangol, J., Marieie, A., Valencie, M., et al., *Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients*. *Coll Antropol*, 2008. **32**(Suppl 2):79-81.
3. Boyd, L.A., *Are we doing enough to promote bone health in men with prostate cancer?* *Urol Nursing*, 2008. **28**(6):412-3.
4. Saad, F., Adachi, J.D., Brown, J.P., et al., *Cancer treatment-induced bone loss in breast and prostate cancer*. *J Clin Oncol*, 2008. **26**(33): 5465-76.
5. Maxwell, C., *Cancer treatment-induced bone loss in patients with breast or prostate cancer*. *Onc Nursing Forum*, 2005. **32**(3): 589-601.
6. Weingard, K.K., *Nursing implications of androgen deprivation therapy-associated bone loss*. *Urol Nursing*, 2006. **26**(4):261-9.
7. Drudge-Coates, L., *Bone health: the effect of androgen deprivation therapy in prostate cancer patients*. *Intl J Urol Nursing*, 2007. **1**(1): 18-26.
8. Michaud, LB, and Goodin, S., *Cancer-treatment-induced bone loss, part 2*. *Am J Health-Syst Pharm*, 2006. **63**: 534-46.
9. Brufsky, A.M., *Cancer treatment-induced bone loss: pathophysiology and clinical perspectives*. *The Oncologist*, 2008. **13**:187-95.